Agios Pharmaceuticals (AGIO)
$44.08 0.17 (0.38%)
16:44 EST AGIO Stock Quote Delayed 15 Minutes
Previous Close -
Market Cap 2.54B
PE Ratio -6.46
Volume (Avg. Vol.) 772,900
Day's Range 43.39 - 44.97
52-Week Range 28.36 - 68.94
Dividend & Yield N/A (N/A)
AGIO Stock Predictions, Articles, and Agios Pharmaceuticals News
- From InvestorPlace
- From the Web
Big biotech buyouts have already started happening. These five biotech stocks could be the next to go.
Celgene buying out Agios would make sense but either way the company's work on cellular metabolism and gene deleting is interesting the bulls the most. Agios stock is a good buy on its own merits.
These seven rare stocks have received only "buy" ratings from Wall Street's best analysts, with more upside predicted to come.
Recent 13-D and 13-G filings are windows into activist investors activity. We look at Liberty Sirius XM Group and 11 others
This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Why Agios Pharmaceuticals Inc (AGIO), LPL Financial Holdings Inc (LPLA) and Humana Inc (HUM) Are 3 of Today’s Worst Stocks
Agios (AGIO), LPL Financial (LPLA) and Humana (HUM) were wishing the weekend could have lasted one more day on Monday.
These 10 stocks to buy are the perfect way to load up before the seasonally strong October-through-December period.
This week, 22 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Here's why Agios Pharmaceuticals Inc (AGIO), Zulily Inc (ZU) and Aruba Networks, Inc. (ARUN) are three of today's worst stocks.
This week, 11 biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
The grades of eight biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
Navellier RatingsPowered by Portfolio Grader